Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients

Clin Infect Dis. 2008 Apr 1;46(7):1127-9. doi: 10.1086/529394.
No abstract available

Publication types

  • Letter
  • Randomized Controlled Trial

MeSH terms

  • Adenine / administration & dosage
  • Adenine / analogs & derivatives*
  • Adult
  • Aged
  • Anti-HIV Agents / administration & dosage*
  • Atazanavir Sulfate
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives*
  • Drug Therapy, Combination
  • Emtricitabine
  • Female
  • HIV Infections / drug therapy*
  • Humans
  • Male
  • Middle Aged
  • Nevirapine / administration & dosage*
  • Oligopeptides / administration & dosage
  • Organophosphonates / administration & dosage*
  • Pyridines / administration & dosage
  • RNA, Viral / blood
  • Tenofovir
  • Treatment Outcome
  • Viral Load*

Substances

  • Anti-HIV Agents
  • Oligopeptides
  • Organophosphonates
  • Pyridines
  • RNA, Viral
  • Deoxycytidine
  • Atazanavir Sulfate
  • Nevirapine
  • Tenofovir
  • Emtricitabine
  • Adenine